Evidence map›Paper›PMID 37935965›Full record

ArticleScientific reports2023

Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave.

Yun Shan Goh, Siew-Wai Fong, Matthew Zirui Tay, Angeline Rouers, Zi Wei Chang, Jean-Marc Chavatte, Pei Xiang Hor, Chiew Yee Loh, Yuling Huang, Yong Jie Tan and 16 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 2 countries.

Yun Shan GohA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Siew-Wai FongA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Matthew Zirui TayA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Angeline RouersA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Zi Wei ChangA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Jean-Marc ChavatteNational Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore.
Pei Xiang HorA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Chiew Yee LohA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Yuling HuangA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Yong Jie TanA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Bei WangSingapore Immunology Network, A*STAR, Singapore, Singapore.
Eve Zi Xian NgohSingapore Immunology Network, A*STAR, Singapore, Singapore.
Siti Nazihah Mohd SallehSingapore Immunology Network, A*STAR, Singapore, Singapore.
Raphael Tze Chuen LeeBioinformatics Institute, A*STAR, Singapore, Singapore.
Georgina LimMinistry of Health (MOH), Singapore, Singapore.
NCID Study Group
COVID-Study Group
Sebastian Maurer-StrohA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Cheng-I WangSingapore Immunology Network, A*STAR, Singapore, Singapore.
Yee-Sin LeoNational Centre for Infectious Diseases (NCID), Singapore, Singapore.
Raymond T P LinNational Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore.
Meng Chon LamMinistry of Health (MOH), Singapore, Singapore.
David C LyeNational Centre for Infectious Diseases (NCID), Singapore, Singapore.
Barnaby Edward Young *National Centre for Infectious Diseases (NCID), Singapore, Singapore.
Lisa F P Ng *A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
Laurent Renia *A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore. renia_laurent@idlabs.a-star.edu.sg.
Agency for Science, Technology and Research · SGNational Centre for Infectious Diseases · SGMinistry of Health · SGNanyang Technological University · SGNational University of Singapore · SGUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of the risk factors and the high-risk groups which are most vulnerable is critical in COVID-19 disease management at a population level. Evaluating the efficacy of vaccination against infections is necessary to determine booster vaccination strategies for better protection in high-risk groups. In this study, we recruited 158 mRNA-vaccinated individuals during the Delta wave of SARS-CoV-2 infections in Singapore and examined the antibody profiles of infected individuals. We found that, despite high exposure due to communal living conditions in proximity, 4% of individuals (6/158) had PCR-confirmed infections and 96% (152/158) remained uninfected. Time-course analysis of the antibody profile at the start and the end of quarantine period showed Delta-specific boosting of anti-spike antibody response in 57% of the uninfected individuals (86/152). In the remaining 43% of the uninfected individuals (66/152) with no Delta-specific antibody boost, we found a higher Delta-specific antibody response at the start of quarantine period, which correlated with higher Delta pseudovirus neutralizing capacity. Our findings indicate that a higher basal variant-specific antibody response in the mRNA-vaccinated individuals contributes to better protection against infections by the new emerging SARS-CoV-2 variants.

Indexed as

Antibodies, NeutralizingCOVID-19Antibodies, ViralHumansmRNA VaccinesRNA, MessengerSARS-CoV-2VaccinationAntibodies, NeutralizingAntibodies, ViralmRNA VaccinesRNA, Messenger

Identifiers

PMID37935965
PMCPMC10630438
OpenAlexW4388465512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.